Teva Pharmaceutical Industries Limited
TEVAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 4, 2026 | H.C. Wainwright | Douglas Tsao | $54.00(+29%) | $41.91 | StreetInsider |
| Oct 15, 2026 | Barclays | Glen Santangelo | $47.00(+15%) | $40.72 | TheFly |
| Oct 12, 2026 | Raymond James | $50.00(+22%) | $41.10 | StreetInsider | |
| Sep 23, 2026 | Oppenheimer | Les Sulewski | $50.00(+27%) | $39.52 | TheFly |
| Sep 9, 2026 | Leerink Partners | $45.00(+22%) | $36.76 | TheFly | |
| Sep 4, 2026 | UBS | Ashwani Verma | $48.00(+31%) | $36.62 | StreetInsider |
| Aug 12, 2026 | Barclays | $42.00(+15%) | $36.48 | TheFly | |
| Jul 28, 2026 | Piper Sandler | David Amsellem | $44.00(+42%) | $31.08 | TheFly |
| May 6, 2026 | Barclays | $40.00(+12%) | $35.86 | TheFly | |
| Apr 30, 2026 | Piper Sandler | $42.00(+19%) | $35.38 | TheFly | |
| Apr 30, 2026 | UBS | $42.00(+19%) | $35.38 | TheFly | |
| Mar 4, 2026 | Piper Sandler | David Amsellem | $41.00(+26%) | $32.64 | StreetInsider |
| Jan 30, 2026 | Barclays | Glen Santangelo | $38.00(+15%) | $33.07 | TheFly |
| Jan 29, 2026 | Scotiabank | $40.00(+22%) | $32.90 | TheFly | |
| Jan 7, 2026 | Truist Financial | $36.00(+12%) | $32.11 | TheFly | |
| Jan 6, 2026 | Jefferies | $40.00(+29%) | $31.00 | TheFly | |
| Dec 22, 2025 | Piper Sandler | $40.00(+32%) | $30.35 | TheFly | |
| Dec 18, 2025 | Goldman Sachs | $35.00(+16%) | $30.06 | TheFly | |
| Dec 8, 2025 | Barclays | $35.00(+24%) | $28.33 | TheFly | |
| Dec 4, 2025 | Scotiabank | $35.00(+23%) | $28.41 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Leerink Partners | maintain | Outperform | Nov 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 4, 2026 |
| TD Cowen | maintain | Buy | Nov 4, 2026 |
| Barclays | maintain | Overweight | Oct 15, 2026 |
| JP Morgan | maintain | Overweight | Oct 12, 2026 |
| UBS | maintain | Buy | Sep 4, 2026 |
| Barclays | maintain | Overweight | Aug 12, 2026 |
| Piper Sandler | maintain | Overweight | Jul 28, 2026 |
| Barclays | maintain | Overweight | May 6, 2026 |
| JP Morgan | maintain | Overweight | Apr 30, 2026 |
| Truist Securities | maintain | Buy | Apr 30, 2026 |
| Piper Sandler | maintain | Overweight | Apr 30, 2026 |
| UBS | maintain | Buy | Apr 30, 2026 |
| B of A Securities | maintain | Buy | Apr 9, 2026 |
| Piper Sandler | maintain | Overweight | Mar 4, 2026 |
| Truist Securities | maintain | Buy | Feb 18, 2026 |
| Goldman Sachs | maintain | Buy | Feb 9, 2026 |
| Barclays | maintain | Overweight | Jan 30, 2026 |
| Truist Securities | maintain | Buy | Jan 29, 2026 |
| Scotiabank | maintain | Sector Outperform | Jan 29, 2026 |
| Jefferies | maintain | Buy | Jan 6, 2026 |
| Piper Sandler | maintain | Overweight | Dec 22, 2025 |
| Goldman Sachs | maintain | Buy | Dec 19, 2025 |
| JP Morgan | maintain | Overweight | Dec 16, 2025 |
| B of A Securities | maintain | Buy | Dec 9, 2025 |
Earnings History
Next report: Jan 27, 2027 · EPS est. $0.69| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $0.86 | $0.72 | $4.39B | $4.23B |
| Jul 29, 2026 | $0.02 | $0.08 | $4.14B | $4.08B |
| Apr 29, 2026 | $0.53 | $0.50 | $3.98B | $3.79B |
| Jan 28, 2026 | $0.96 | $0.65 | $4.71B | $4.32B |
| Nov 5, 2025 | $0.78 | $0.68 | $4.48B | $4.45B |
| Jul 30, 2025 | $0.66 | $0.63 | $4.18B | $4.36B |
| May 7, 2025 | $0.52 | $0.47 | $3.89B | $4.38B |
| Jan 29, 2025 | $0.71 | $0.69 | $4.23B | $4.10B |
News
Teva improved margins significantly. The pharmaceutical company has paid down net debt.
Teva Pharmaceutical Industries (NYSE: TEVA) reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-drug sales, particularly generic REVLIMID. Chief Executive Officer Richard Francis said the company's innovative portfolio grew 32% year over year, led by AUSTEDO, AJOVY and UZEDY.
Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.
Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-drug sales, particularly generic REVLIMID.
Teva Pharmaceutical Industries Limited ( TEVA ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Richard Francis - President, CEO & Director Eric Hughes - Executive VP of Global R&D and Chief Medical Officer Eliyahu Kalif - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Res…
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva Pharmaceutical Q3 profit gain beats estimates
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's commercial capabilities Agreement expands collaboration with Samsung Bioepis, strengthening Teva's generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (…
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin in adult patients with multiple system atrophy.
Teva to discontinue mid-stage neurodegenerative disorder study
Wall Street analysts are making bold moves this week, with dramatic target price cuts on some high-flying names and surprise upgrades on stocks that took a beating in October. Which calls deserve your attention before the market opens?
Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and several high-potential pipeline drugs could add $5.5B–$9B in annual peak sales, driving significant revenue growth. Financials are markedly improved: debt halved since 2017, cash balance rising, and revenue rebounding, positioning TEVA for further upside.
Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher price levels.
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva's ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript